Photo from wikipedia
Major changes have emerged during the last few years in the therapy of chronic HCV. Several direct acting antiviral agents have been developed showing potent activity with higher rates of… Click to show full abstract
Major changes have emerged during the last few years in the therapy of chronic HCV. Several direct acting antiviral agents have been developed showing potent activity with higher rates of sustained virological response, even in difficult‐to‐treat patients. This study explores real life experience concerning efficacy, safety and possible predictors of response for the first cohort of Egyptian patients with chronic HCV genotype IV treated with Sofosbuvir/Simprevir combination therapy.
Keywords:
efficacy safety;
chronic hcv;
hcv genotype;
real life;
experience
Journal Title: Liver International
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Liver International
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!